User:Adam Davis/Sandbox 1: Difference between revisions
From Proteopedia
Jump to navigationJump to search
Adam Davis (talk | contribs) No edit summary |
Adam Davis (talk | contribs) No edit summary |
||
| Line 21: | Line 21: | ||
== Disease == | == Disease == | ||
PPARδ agonists are being investigated as treatments for a number of metabolic disorders including dyslipidemia, Type 2 Diabetes, and cardiovascular disease. Though there are some health benefits associates with PPARα and γ agonists, these drugs also have undesirable side effects including such as edema and weight gain for PPARα, and carcinogenicity for PPARγ<ref>DOI 10.1038/35013000</ref>. If PPARδ agonists are to be used clinically, it is thus important to develop a ligand that | PPARδ agonists are being investigated as treatments for a number of metabolic disorders including dyslipidemia, Type 2 Diabetes, and cardiovascular disease. Though there are some health benefits associates with PPARα and γ agonists, these drugs also have undesirable side effects including such as edema and weight gain for PPARα, and carcinogenicity for PPARγ<ref>DOI 10.1038/35013000</ref>. If PPARδ agonists are to be used clinically, it is thus important to develop a ligand that does not also bind to the other PPARs. | ||
== Relevance == | == Relevance == | ||
